TriSalus Life Sciences, Inc. (TLSI) - What Are Analysts Thinking About This Stock?

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) have earned a consensus recommendation of "Hold" from the five analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $10.20.

TLSI has been the subject of a number of analyst reports. HC Wainwright increased their price target on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the company a "buy" rating in a report on Wednesday, September 23rd. Zacks Research upgraded shares of TriSalus Life Sciences to a "hold" rating in a report on Thursday, September 10th. Guggenheim set a $12.00 price objective on TriSalus Life Sciences in a research report on Wednesday, September 23rd. Wall Street Zen upgraded TriSalus Life Sciences from a "sell" rating to a "hold" rating in a research report on Sunday, August 23rd. Finally, Stifel Nicolaus set a $12.00 target price on shares of TriSalus Life Sciences in a research note on Wednesday, September 23rd.

TriSalus Life Sciences Stock Up 3.4%

TriSalus Life Sciences stock opened at $3.93 on Thursday. The company has a current ratio of 5.35, a quick ratio of 4.97 and a debt-to-equity ratio of 5.05. The firm has a market cap of $241.99 million, a price-to-earnings ratio of -3.02 and a beta of 0.47. The stock has a fifty day simple moving average of $4.50 and a two-hundred day simple moving average of $4.44. TriSalus Life Sciences has a 12 month low of $2.20 and a 12 month high of $7.95.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.16). The firm had revenue of $11.41 million during the quarter, compared to analysts' expectations of $10.27 million. Equities analysts predict that TriSalus Life Sciences will post -0.53 EPS for the current fiscal year.

Hedge Funds Weigh In On TriSalus Life Sciences

Hedge funds have recently added to or reduced their stakes in the stock. First Light Asset Management LLC purchased a new position in TriSalus Life Sciences during the 1st quarter worth $20,267,000. BlackRock Inc. purchased a new stake in shares of TriSalus Life Sciences in the 2nd quarter worth $12,099,000. Nantahala Capital Management LLC purchased a new stake in shares of TriSalus Life Sciences in the 2nd quarter worth $4,550,000. State Street Corp grew its position in shares of TriSalus Life Sciences by 86.3% during the 2nd quarter. State Street Corp now owns 610,963 shares of the company's stock worth $2,780,000 after buying an additional 282,943 shares in the last quarter. Finally, Perkins Capital Management Inc. bought a new position in shares of TriSalus Life Sciences during the 1st quarter worth $920,000. 2.58% of the stock is currently owned by institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences is an oncology-focused healthcare company developing technologies and therapies for patients with liver and pancreatic tumors. The company combines medical devices, drug-delivery systems and immunotherapy programs to address tumors that may be difficult to treat with conventional approaches.

Its core technology is Pressure-Enabled Drug Delivery (PEDD), a platform designed to improve the delivery of therapeutic agents directly to tumors through the arterial blood supply.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.